Karyopharm reports Q4 EPS (43c), consensus (35c)

Reports Q4 revenue $33.6M, consensus $35.12M. Cash, cash equivalents, restricted cash and investments as of December 31, 2022 totaled $279.7M vs. $235.6M as of December 31, 2021. "In 2022, Karyopharm delivered strong financial performance with a 22% increase in U.S. XPOVIO net product revenue, coupled with significant progress across our clinical pipeline and the achievement of several key regulatory milestones. Importantly, we solidified our financial runway to late 2025, enabling us to be well positioned to deliver the next stages of the company’s growth," said CEO Richard Paulson. "Moving forward in 2023, we are excited to advance our mid-late stage pipeline and anticipate multiple data catalysts and robust progress across our programs in multiple myeloma, endometrial cancer, myelofibrosis and myelodysplastic neoplasms. We are passionate in our pursuit to bring forward innovative treatments that address critical unmet needs and positively impact the lives of people living with cancer."